In August, the Boston-based drugmaker stopped manufacturing Auryxia due to issues with its manufacturer over converting active pharmaceutical ingredients into finished pills.
On Wednesday, the FDA approved the use of a second manufacturer, allowing Keryx to reinitiate manufacturing processes and supply the drug to wholesalers.
“Getting a second drug product manufacturer approved was an important step to ensuring long-term supply of Auryxia is consistently available to patients,” said Keryx CEO Greg Madison in a statement.
More articles on supply chain:
FDA may allow medical companies to promote drugs, devices for off-label uses
J.B. Hunt to add hundreds of trucks next year despite industry slowdown: 3 takeaways
Global supply chain risk index on the rise: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
